TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24755339

Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemofiltration (CVVH) with no anticoagulation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemofiltration (CVVH) with unfractionated heparin
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemofiltration (CVVH) with trisodium citrate
Number of subjects: 42

Group type: COMPARATOR
Intervention: Citrate-based CVVH
Number of subjects: 42

Group type: COMPARATOR
Intervention: All anticoagulation methods
Number of subjects: 42
Study: 23041343

Group type: EXPERIMENTAL
Intervention: Rectal cleansing with povidone-iodine
Number of subjects: 865

Group type: COMPARATOR
Intervention: No cleansing (control)
Number of subjects: 865
Study: 20599398

Group type: EXPERIMENTAL
Intervention: Early postoperative statin use
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Statin withdrawal
Number of subjects: 324

Group type: COMPARATOR
Intervention: Preoperative statin use
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control group (no early postoperative statin use)
Number of subjects: 324
Study: 18004285

Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC), 2 g/day for 60 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15713149

Group type: EXPERIMENTAL
Intervention: LigaSure vessel sealing system
Number of subjects: 116

Group type: COMPARATOR
Intervention: Suture ligation
Number of subjects: 116
Study: 12941675

Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg/d)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 376
Study: 10907625

Group type: EXPERIMENTAL
Intervention: Troglitazone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (sulfonylureas only)
Number of subjects: 32
Study: 2189551

Group type: COMPARATOR
Intervention: 5‐fluorouracil (5‐FU) alone
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Mallinson regimen (combined and sequential 5‐FU, cyclophosphamide, methotrexate, vincristine, and mitomycin C)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Combined 5‐FU, doxorubicin, and cisplatin (FAP)
Number of subjects: 187
Study: 478714

Group type: EXPERIMENTAL
Intervention: 3-week treatment program
Number of subjects: 86

Group type: COMPARATOR
Intervention: 5-week treatment program
Number of subjects: 86
Study: 31425230

Group type: EXPERIMENTAL
Intervention: Continuous bilateral paravertebral block (PVB)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Thoracic epidural analgesia (TEA)
Number of subjects: 70
Study: 28357966

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 86

Group type: COMPARATOR
Intervention: Relaxation therapy
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation and Relaxation therapy
Number of subjects: 86
Study: 25912560

Group type: EXPERIMENTAL
Intervention: ASV plus guideline-directed medical therapy (GDMT)
Number of subjects: 213

Group type: COMPARATOR
Intervention: GDMT only
Number of subjects: 213
Study: 24751470

Group type: EXPERIMENTAL
Intervention: Oxandrolone (0.05 mg/kg/day; max: 2.5 mg/day)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Ethinylestradiol (2 µg/day in year 1, 4 µg/day in year 2, 6/8/10 µg/day in year 3 for 4 months)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Spontaneous puberty
Number of subjects: 92
Study: 22065235

Group type: EXPERIMENTAL
Intervention: HIV and Abuse Related Shame Inventory (HARSI)
Number of subjects: 271
Study: 19129278

Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone (SFP) 100/1,000 microg daily
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Tiotropium/fluticasone (Tio+FP) 18/1,000 microg daily
Number of subjects: 99

Group type: COMPARATOR
Intervention: Tiotropium (Tio) 18 microg daily
Number of subjects: 99
Study: 17285888

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glutamine (enterally or parenterally)
Number of subjects: 0

Group type: COMPARATOR
Intervention: G-CSF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 0
Study: 14583440

Group type: EXPERIMENTAL
Intervention: 15 g of essential amino acids (EAA)
Number of subjects: 13
Study: 11695213

Group type: EXPERIMENTAL
Intervention: New dentifrice formulation (Colgate Total Plus Whitening Toothpaste)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Colgate Total Toothpaste (control)
Number of subjects: 86
Study: 10682134

Group type: EXPERIMENTAL
Intervention: Zidovudine/Lamivudine
Number of subjects: 1083
Study: 7643045

Group type: EXPERIMENTAL
Intervention: Task level programming (determination of the trajectory of a hand during arm reaching in Cartesian coordinates)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manipulator level programming (determination of the joint coordinates)
Number of subjects: 0
Study: 2492741

Group type: EXPERIMENTAL
Intervention: Nifedipine (40 to 120 mg/day)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Diltiazem (120 to 360 mg/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 6999946

Group type: EXPERIMENTAL
Intervention: Intravenous physostigmine salicylate (2.0 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 30455077

Group type: EXPERIMENTAL
Intervention: 10 × 10^6/kg predicted bodyweight MSCs
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28736293

Group type: EXPERIMENTAL
Intervention: Zirconia-based crowns (Zircad/Zirpress)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Metal-based crowns (porcelain fused to metal)
Number of subjects: 72
Study: 26243349

Group type: EXPERIMENTAL
Intervention: Group therapy module A (4 hours per week for 8 weeks)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group therapy module B (4 hours per week for 8 weeks)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual treatments (control group not explicitly defined in the abstract)
Number of subjects: 120
Study: 25604019

Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiochemotherapy followed by surgery (RCS group)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy followed by surgery (NCS group)
Number of subjects: 56
Study: 22594362

Group type: EXPERIMENTAL
Intervention: Medical simulation-based educational intervention (12 participants)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Current EM curriculum (15 participants)
Number of subjects: 27
Study: 20818863

Group type: EXPERIMENTAL
Intervention: Chest compression alone
Number of subjects: 1941

Group type: COMPARATOR
Intervention: Chest compression plus rescue breathing
Number of subjects: 1941
Study: 18811097

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (Dycal) base
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zinc oxide‐eugenol (Kalzinol) base
Number of subjects: 0
Study: 15699931

Group type: EXPERIMENTAL
Intervention: Successful recanalization (n=28)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Unsuccessful recanalization (n=24)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Successful recanalization survivors
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Successful recanalization nonsurvivors
Number of subjects: 52
Study: 11923809

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (50 mg oral dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9934939

Group type: EXPERIMENTAL
Intervention: Testosterone therapy (400 mg of intramuscular testosterone cypionate biweekly for 8 weeks)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Testosterone therapy
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 7769069

Group type: EXPERIMENTAL
Intervention: Fresh embryo transfer
Number of subjects: 24

Group type: COMPARATOR
Intervention: Frozen embryo transfer
Number of subjects: 24
Study: 2110575

Group type: EXPERIMENTAL
Intervention: Enteral glucose infusion with gastric inhibitory polypeptide
Number of subjects: 7

Group type: COMPARATOR
Intervention: IV glucose administration
Number of subjects: 7
Study: 7460479

Group type: EXPERIMENTAL
Intervention: 0.25 mg intramuscular ergotamine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2 mg sublingual ergotamine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sublingual placebo
Number of subjects: 12
Study: 31045765

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Language Therapy (CBLT)
Number of subjects: 86

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 86
Study: 28241723

Group type: EXPERIMENTAL
Intervention: Coflex
Number of subjects: 38

Group type: COMPARATOR
Intervention: Pedicle instrumentation and interbody fusion
Number of subjects: 38
Study: 25549169

Group type: EXPERIMENTAL
Intervention: Level-dependent mode of hearing protection (Peltor® PowerCom Plus™ and Nacre QuietPro®)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional hearing protection (level-dependent mode switched off)
Number of subjects: 45
Study: 24633268

Group type: EXPERIMENTAL
Intervention: PHiD-CV
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: PHiD-CV and Control
Number of subjects: 119
Study: 19939874

Group type: EXPERIMENTAL
Intervention: Nicotine gum (6 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 19945934

Group type: EXPERIMENTAL
Intervention: Problem-based evidence (PBE) methodology
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 17902519

Group type: EXPERIMENTAL
Intervention: Holmium YAG laser (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pneumatic lithoclast (Group B)
Number of subjects: 60
Study: 15036672

Group type: EXPERIMENTAL
Intervention: End-cut needle (BioPince) with stroke lengths of 13mm, 23mm, and 33mm
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard side-notch needle
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: End-cut needle (BioPince) with 33mm stroke length
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: End-cut needle (BioPince) with stroke lengths of 13mm and 23mm
Number of subjects: 86
Study: 11702866

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch and nimodipine for an average of 9 days
Number of subjects: 41

Group type: COMPARATOR
Intervention: No postoperative medical treatment
Number of subjects: 41
Study: 9393050

Group type: EXPERIMENTAL
Intervention: Pressure-relief mattresses
Number of subjects: 0
Study: 7948449

Group type: EXPERIMENTAL
Intervention: Pentagastrin infusion
Number of subjects: 20
Study: 3371138

Group type: EXPERIMENTAL
Intervention: Carprofen (150 mg twice daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Indomethacin (25 mg four times daily)
Number of subjects: 40
Study: 29277125

Group type: EXPERIMENTAL
Intervention: 100% subsidy
Number of subjects: 23023

Group type: EXPERIMENTAL
Intervention: 80% subsidy
Number of subjects: 23023

Group type: EXPERIMENTAL
Intervention: 50% subsidy
Number of subjects: 23023

Group type: EXPERIMENTAL
Intervention: Hybrid 50% subsidy
Number of subjects: 23023

Group type: COMPARATOR
Intervention: All groups (100%, 80%, 50%, hybrid)
Number of subjects: 23023
Study: 26889992

Group type: EXPERIMENTAL
Intervention: Bipolar sealer device
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no bipolar sealer device)
Number of subjects: 100
Study: 26386801

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) designed to achieve and maintain weight loss through caloric reduction and increased physical activity
Number of subjects: 5067

Group type: COMPARATOR
Intervention: Diabetes support and education usual care group
Number of subjects: 5067

Group type: EXPERIMENTAL
Intervention: Weight loss during the first year of the intervention
Number of subjects: 5067

Group type: EXPERIMENTAL
Intervention: Improvement in physical fitness during the first year of the intervention
Number of subjects: 5067
Study: 24076594

Group type: EXPERIMENTAL
Intervention: Calcitriol (0.25 μg 1,25-dihydroxy cholecalciferol per capsule, 2 capsules per day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 70
Study: 20107916

Group type: EXPERIMENTAL
Intervention: In-person interpretation
Number of subjects: 241

Group type: COMPARATOR
Intervention: Video interpretation
Number of subjects: 241

Group type: COMPARATOR
Intervention: Telephonic interpretation
Number of subjects: 241

Group type: COMPARATOR
Intervention: All methods (in-person, video, telephonic)
Number of subjects: 241
Study: 19113053

Group type: EXPERIMENTAL
Intervention: Closed wound drainage with suction (26 patients)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Closed wound drainage without suction (24 patients)
Number of subjects: 50
Study: 16009883

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a 30 microg IM once weekly
Number of subjects: 795

Group type: COMPARATOR
Intervention: Interferon beta‐1a 60 microg IM once weekly
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: NAb+ patients
Number of subjects: 795
Study: 12616704

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (40-kDa), 180 micrograms subcutaneous once-weekly, and ribavirin, 400 mg b.i.d. for 44 additional weeks after initial therapy
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (40-kDa), 180 micrograms subcutaneous once-weekly, and ribavirin, 400 mg b.i.d. for 68 additional weeks after initial therapy
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (40-kDa), 180 micrograms subcutaneous once-weekly, and ribavirin, 400 mg b.i.d. for 20 additional weeks after initial therapy
Number of subjects: 504

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 504
Study: 10357339

Group type: EXPERIMENTAL
Intervention: Clonidine (150 microg) added to 40 mL of 0.5% lidocaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isotonic saline added to 40 mL of 0.5% lidocaine (Control)
Number of subjects: 40
Study: 8603942

Group type: EXPERIMENTAL
Intervention: pentavalent Corynebacterium diphtheriae C7 (beta197) CRM197 protein‐conjugated pneumococcal vaccine (CV)
Number of subjects: 46

Group type: COMPARATOR
Intervention: licensed (23‐valent, 25 microgram/serotype) pneumococcal polysaccharide vaccine (PV)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: reimmunization with PV after initial CV
Number of subjects: 46
Study: 1758717

Group type: EXPERIMENTAL
Intervention: Polyurethane (PU) catheters
Number of subjects: 300

Group type: COMPARATOR
Intervention: Polyethylene (PE) catheters
Number of subjects: 300
Study: 7199854

Group type: EXPERIMENTAL
Intervention: 30 mg of cocaine HCl solution administered intranasally
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal saline placebo administered intranasally
Number of subjects: 16
Study: 31752964

Group type: EXPERIMENTAL
Intervention: Integrated electronic health record (EHR) and community health worker (CHW) intervention including group education sessions on diabetes prevention, weight loss, and nutrition.
Number of subjects: 480

Group type: COMPARATOR
Intervention: Matched control group receiving standard care without the integrated EHR and CHW intervention.
Number of subjects: 480
Study: 29371080

Group type: EXPERIMENTAL
Intervention: Otoscopy Simulation (OS)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Web-based Module (WM)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Standard Instruction (SI)
Number of subjects: 29
Study: 26685106

Group type: EXPERIMENTAL
Intervention: 3D TSE MRI with 6-fold acceleration (10-minute protocol)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 2D TSE MRI (20-minute protocol)
Number of subjects: 30
Study: 25451907

Group type: EXPERIMENTAL
Intervention: Telephone delivered translation of the DPP weight loss program, delivered by trained primary care staff over 2 years.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual calls (control group).
Number of subjects: 0
Study: 22065199

Group type: EXPERIMENTAL
Intervention: Temozolomide plus radiotherapy
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: MGMT subgroup analysis
Number of subjects: 215

Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 215

Group type: COMPARATOR
Intervention: Complete resection
Number of subjects: 215

Group type: COMPARATOR
Intervention: Postprogression second surgery
Number of subjects: 215
Study: 19233759

Group type: EXPERIMENTAL
Intervention: Off-pump CABG surgery
Number of subjects: 66
Study: 16501591

Group type: EXPERIMENTAL
Intervention: Topotecan at 4.0 mg/m2/day x 5 days
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Topotecan at 7 mg/m2/day
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Topotecan at 9.5 mg/m2/day
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Topotecan at 9 mg/m2/day x 5 days
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Topotecan at 4-9.0 mg/m2/day
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Topotecan at 9 mg/m2/day
Number of subjects: 49
Study: 12573207

Group type: EXPERIMENTAL
Intervention: Birch/hazel-SLIT + Grass-SIT
Number of subjects: 36

Group type: COMPARATOR
Intervention: Grass-SIT
Number of subjects: 36
Study: 11004067

Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA) clamped
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Classic laryngeal mask airway (LMA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA) unclamped
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no airway device)
Number of subjects: 10
Study: 8842660

Group type: EXPERIMENTAL
Intervention: rocuronium 0.6 mg kg‐1
Number of subjects: 90

Group type: COMPARATOR
Intervention: suxamethonium 1 mg kg‐1
Number of subjects: 90
Study: 1588355

Group type: EXPERIMENTAL
Intervention: Rowasa I (placebo-controlled)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6386486

Group type: EXPERIMENTAL
Intervention: penbutolol 40 mg single dose
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: combined therapy (penbutolol + molsidomine 2 mg single dose)
Number of subjects: 30

Group type: COMPARATOR
Intervention: beta blocker alone
Number of subjects: 30
Study: 31648204

Group type: EXPERIMENTAL
Intervention: Multimodal Training (MMT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Single-Modal Training (SMT)
Number of subjects: 21
Study: 29494424

Group type: EXPERIMENTAL
Intervention: Direct delivery of HIV self-tests from a peer educator
Number of subjects: 965

Group type: EXPERIMENTAL
Intervention: Free facility-based delivery of HIV self-tests in exchange for coupons
Number of subjects: 965

Group type: COMPARATOR
Intervention: Standard-of-care HIV testing
Number of subjects: 965
Study: 26891621

Group type: EXPERIMENTAL
Intervention: Developmental individual‐difference, relationship‐based/floortime (DIR/FT) group (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Psychoeducational (wait-list) group (n = 20)
Number of subjects: 40
Study: 24687927

Group type: EXPERIMENTAL
Intervention: Adjuvant FOLFOX alone or combined with cetuximab
Number of subjects: 2478

Group type: COMPARATOR
Intervention: Wild-type KRAS/BRAF tumors
Number of subjects: 2478
Study: 22704583

Group type: EXPERIMENTAL
Intervention: Oral clodronate 1600 mg daily for 3 years
Number of subjects: 3323

Group type: EXPERIMENTAL
Intervention: Oral clodronate 1600 mg daily for 3 years (in women age 50 years or older)
Number of subjects: 3323

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3323
Study: 20715086

Group type: EXPERIMENTAL
Intervention: Endoscopic-assisted adenoidectomy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Curettage adenoidectomy
Number of subjects: 38
Study: 17005329

Group type: EXPERIMENTAL
Intervention: Standard treatment plus contingency management
Number of subjects: 393

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 393
Study: 17319251

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% plus tramadol 100 mg (Group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% plus clonidine 1 microg/kg (Group 3)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bupivacaine 0.5% (Group 1)
Number of subjects: 60
Study: 11978744

Group type: EXPERIMENTAL
Intervention: Midwife
Number of subjects: 826

Group type: COMPARATOR
Intervention: SHO (junior paediatrician)
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Discussion of healthcare issues
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Continuity of care
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: History of miscarriage
Number of subjects: 826
Study: 9916961

Group type: EXPERIMENTAL
Intervention: IV nitroglycerin
Number of subjects: 31

Group type: COMPARATOR
Intervention: IV magnesium sulfate
Number of subjects: 31
Study: 7754537

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) by electron beam
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (non-IORT)
Number of subjects: 54
Study: 2076398

Group type: EXPERIMENTAL
Intervention: 10 mg slow-release nifedipine
Number of subjects: 9

Group type: COMPARATOR
Intervention: 5 mg isosorbide dinitrate
Number of subjects: 9
Study: 7000243

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/day)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Long-acting propranolol (160 mg/day)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Sustained-release oxprenolol (160 mg/day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 31690616

Group type: EXPERIMENTAL
Intervention: Incremental PEEP titration (randomized to -6, -3, +3, and +6 cm H2O)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Transpulmonary pressure positive
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Inter-operator variability assessment
Number of subjects: 14
Study: 30796496

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) with 20 Gy (arm-A)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Postoperative whole-breast radiation therapy (WBRT) up to 56 Gy in 2 Gy fractions (arm-B)
Number of subjects: 184
Study: 27450571

Group type: EXPERIMENTAL
Intervention: Psychotherapy-based text messaging (daily messages 6 days per week for 12 weeks)
Number of subjects: 190
Study: 26225993

Group type: EXPERIMENTAL
Intervention: MVM + G
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23672349

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 219
Study: 20816041

Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54